advertisement

---

Tomita G 12

Showing records 1 to 12 | Display all abstracts from Tomita G

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Inoue K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Inoue K; Shiokawa M
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shiokawa M
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Katakura S
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Kunimatsu-Sanuki S; Nozaki N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tsuruoka M
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shimizu K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Kunimatsu-Sanuki S; Shimizu K
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Ishida K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Ishida K
American Journal of Ophthalmology 2022; 237: 114-121

---

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Tomita G
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358

---

99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tomita G
American Journal of Ophthalmology 2022; 237: 114-121

---